hepatitis B, liver cancer
Conditions
Interventions
Patients with HBV-related liver cancer treated with anti-PD-1/PD-L1 antibody:None
Patients with HBV-related liver cancer without anti-PD-1/PD-L1 antibody therapy:None
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) HBsAg and/or HBV DNA positive for at least 6 months; 2) Liver cancer was diagnosed according to the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition); 3) Prospective follow-up patients should be willing to complete the whole follow-up for 48 weeks.
Exclusion criteria
Exclusion criteria: 1) Pregnant women; 2) Suffering from autoimmune diseases or using immunosuppressants; 3) In addition to liver diseases, other major diseases that may affect immunity;4) For prospective follow-up patients, their health status is too poor, and clinicians judge that they are not suitable for follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;HBV serum markers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Other laboratory indicators(Such as liver function, renal function); | — |
Countries
China
Contacts
Public ContactDazhi Zhang
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed